Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Philip Morris International Inc. (PM) Price & Performance

iShares iBoxx $ Inv Grade Corporate Bond ETFTrade
Philip Morris International Inc.Trade

Price performance (Past 24H)

Key statistics

iShares iBoxx $ Inv Grade Corporate Bond ETF vs Philip Morris International Inc. — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.36 (market cap $28.50B), while Philip Morris International Inc. trades at $200.14 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 11× iShares iBoxx $ Inv Grade Corporate Bond ETF's market cap, and Philip Morris International Inc. pays a 3.19% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days and Philip Morris International Inc. for 85 Days on average.

LQDPM
Market Cap
$28.50B$312.50B
Volume
37,320,1105,517,172
Sector
Fixed IncomeConsumer Staples
52-Week High
$112.91$200.50
52-Week Low
$101.83$144.33
Typical Hold Time
125 Days85 Days
Enterprise Value
—$355.62B
Dividend Yield
—3.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares iBoxx $ Inv Grade Corporate Bond ETF

LQD trades at $102.39 with a slight 0.26% daily gain amid a challenging bond market environment. The ETF faces bearish technical signals with moving averages indicating downward pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September (Defense World, 2026-10-01) and concerns about investment-grade corporate bonds as Treasury yields hit multi-decade highs.

The outlook remains cautious with rising bond yields creating headwinds for corporate bond ETFs. While LQD offers a 4.8% yield with high-quality portfolio exposure, the weak investment thesis noted by Seeking Alpha (2026-09-22) and substantial short interest growth suggest near-term pressure. Investors should monitor Fed policy decisions and corporate bond market stability for directional cues.

Philip Morris International Inc.

Philip Morris International (PM) trades at $192.69, up 1.2% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 EPS beat expectations at $2.20 vs. $2.05, and revenue growth accelerated to $40.65B in 2025. The company's smoke-free products now drive 42% of revenue, with ZYN and IQOS expansions fueling optimism. Cash flow remains robust, with 2026 operating cash flow projected at $14.3B, supporting dividend growth.

Outlook is positive given earnings momentum and smoke-free transition, but high debt ($42.17B long-term) and regulatory risks persist. The consensus price target of $212.17 implies ~10% upside, though valuation multiples are elevated versus peers. Key risks include FX volatility and slower adoption of next-gen products.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LQD

No sentiment data available yet.

PM
1% Buy99% Sell
Avg holding period · 85 Days

Top news

Latest headlines on both assets

About iShares iBoxx $ Inv Grade Corporate Bond ETF

The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.

Read more on LQD →

About Philip Morris International Inc.

Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.

Read more on PM →